| Name |
Kabazitaksel Fresenius Kabi 20 mg/ml koncentrat za otopinu za infuziju |
| Marketing Authorisation Number |
HR-H-764600346 |
| Active Substance |
kabazitaksel |
| Composition |
jedan ml otopine sadrži 20 mg kabazitaksela jedna bočica s 3 ml koncentrata sadrži 60 mg kabazitaksela |
| Pharmaceutical Form |
Koncentrat za otopinu za infuziju |
| Manufacturer |
Fresenius Kabi Deutschland GmbH, Friedberg, Njemačka |
| Marketing Authorisation Holder |
Fresenius Kabi d.o.o., Radnička cesta 37a, Zagreb, Hrvatska |
| Marketing Authorisation Date |
19.08.2022 |
| MA Period of Validity |
19.08.2027 |
| Classification Number |
UP/I-530-09/21-01/65 |
| Registration Number |
381-12-01/70-22-09 |
| Prescription |
Medicinal product subject to medical prescription |
| Type of prescription |
ograničeni recept
|
| Distribution |
Supply through pharmacies (community) |
| Advertising to general public |
not allowed |
| ATC Code |
L01CD04 |
| Marketing status |
nije stavljeno u promet |
| SmPC |
download |
| PL |
download |
| Public Assessment Report |
download
|
